SUPREME-SECURE is a Unitaid-funded program working to strengthen sustainable access to quality-assured diagnostics and treatments for preeclampsia, eclampsia, and maternal anemia in sub-Saharan Africa. CHAI is leading this initiative in partnership with Concept Foundation, Aurum Institute, Burnet Institute, and WACI Health.
As part of the program’s market access work, Concept Foundation is now accepting expressions of interest (EOIs) from manufacturers of hydralazine, labetalol, methyldopa, and nifedipine—inviting partners to help improve the quality, availability, and affordability of these essential maternal health medicines. This EOI will be followed by a closed Request for Proposals (RFP) process.
Target products and dose/presentation:
- Hydralazine:
- 25mg or 50mg tablets
- 20mg vial or ampoule
- Labetalol:
- 100mg tablets
- 5mg/mL vial or ampoule
- Methyldopa:
- 250mg tablets
- Nifedipine:
- 10mg immediate release capsules
- 20mg or 30mg extended release tablets
Target countries include Ghana, Kenya, Malawi, Senegal, and Tanzania, with potential for broader low- and middle-income country reach.
View the EOI on Concept Foundation’s website
Submission deadline: July 24, 2026
Questions? Contact Concept Foundation at rfp_tx@conceptfoundation.org.
